Varian Acquires CyberHeart

Rapid Unit Sales of Medical Masks to Account for Incremental Revenues in the Global Market Through the COVID-19 Crisis Period

Medical facilities are highly dependent on the use of medical masks during surgeries. The availability of different versions of mask for different applications across different end-users, such as ambulatory surgical centre’s, hospitals, dental settings, etc., are expected to fuel the growth of the medical mask market throughout the forecast period.

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.

May 9, 2019: Varian today announced it has acquired CyberHeart, a privately-held company with intellectual property (IP) that covers the use of radiation in the heart (cardiac radioablation) and other forms of radiosurgery for cardiovascular disease.

“Based on the early positive clinical results in ventricular tachycardia we have seen from other investigators, we believe that this technology can offer hope to cardiac arrhythmia patients,” said Dee Khuntia, chief medical officer at Varian. “Cardiac radioablation would truly be a paradigm shift, bringing together two specialties—radiation oncology and cardiac electrophysiology—to collaborate in the treatment of cardiac patients.”

“Varian has a long track record of innovations in the field of radiation medicine and has successfully commercialized radiosurgery technology for treating both benign and malignant lesions,” said Kolleen Kennedy, president of Varian Proton Solutions & chief growth officer.  “We look forward to expanding our focus on patient-centered innovation to the cardiac radioablation space.”

First in-human studies of radioablation in the treatment of cardiac arrhythmias have been published in the New England Journal of Medicine1 and Circulation2.

“While cardiac radioablation technologies are not yet approved by the FDA, we feel that the results of these recent early studies are promising enough to warrant investment in this area,” Kennedy said.  “We’re now working to evaluate the CyberHeart IP portfolio and determine priorities for development and clinical trials going forward.”

Varian’s acquisition of CyberHeart involved the transfer of IP.


References

1 Cuculich, Phillip S., et al. “Noninvasive cardiac radiation for ablation of ventricular tachycardia.” New England Journal of Medicine 377.24 (2017): 2325-2336.

2 Robinson, Clifford G., et al. “Phase I/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia.” Circulation 139.3 (2019): 313-321.

spot_img

DON'T MISS

Related Articles